Seeking Alpha
02 Dec 2025, 23:36 UTC · 49w ago
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data
Impact · against what's priced in
KURA sees a potential valuation lift as Ziftomenib's lack of a QTc prolongation boxed warning provides a safety advantage over SDNX. While upcoming ASH data introduces volatility, the structural safety edge positions KURA to capture market share from Syndax in the NPM1-mutated AML space.
- KURA+0.60
No priced-in read yet
- In context
The avoidance of a QTc prolongation boxed warning gives Ziftomenib a safety edge over its competitor, which could drive physician preference and market share.
Read from the article alone

Top 1 mover · tap to explore




